Transaminase elevation on placebo during Phase I trials: prevalence and significance-Reference-Cited by-同舟云学术

Transaminase elevation on placebo during Phase I trials: prevalence and significance

Published:1999-07 Issue:1 Volume:48 Page:19-23
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:British Journal of Clinical Pharmacology

Author:

Rosenzweig ¹,Miget ¹,Brohier ¹

Affiliation:

1. Department of Clinical Pharmacology, Synthélabo Recherche, 31 avenue Paul Vaillant‐Couturier, 92225 Bagneux Cedex, France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2125.1999.00952.x

Reference11 articles.

1. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective

2. Spriet‐PourraC&AuricheMDrug withdrawal from sale: an analysis of the phenomenon and its implications. Richmond Surrey United Kingdom:Scrip Reports/PJB Publications 1988

3. LymleyCClinical toxicity: could it have been predicted? Pre‐marketing experience. InAnimal Toxicity Studies: Their Relevance for Man eds Lumley CE Walker SR Lancaster UK. Quay 1990:4956

4. Elevated Serum Transaminase Values in Volunteers after Administration of Placebo in a Phase I Study.

5. Elevation of Liver Enzymes in Multiple Dose Trials During Placebo Treatment: Are They Predictable?

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pooled analysis of routine safety parameters observed in healthy participants at baseline and following placebo administration in early phase clinical studies;Clinical and Translational Science;2024-01

2. A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection;Antiviral Therapy;2022-10

3. A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT);PLOS ONE;2022-09-29

4. Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials;Therapeutics and Clinical Risk Management;2021-10

5. Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19;Clinical and Translational Science;2021-08-31